"The duration of disease appears to be a predictor of the presence of renal dysfunction in patients with chronic hypoparathyroidism. In addition, the coexistence of CVD [cardiovascular disease] ...
Hosted on MSN
Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 14, the company delivered positive clinical data from the Phase 3 PaTHway Trial ...
MBX Biosciences (NASDAQ:MBX) stock surged 16% after announcing that its investigational therapy canvuparatide, a once-weekly injection, successfully met the primary endpoint in a Phase 2 trial for ...
MBX Biosciences, Inc. (NASDAQ:MBX) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase ...
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback